Business Context and Reporting Period
This Form 8-K Current Report was filed by Silexion Therapeutics Corp on May 26, 2026. The registrant is a Cayman Islands exempted company with principal executive offices in Ramat-Gan, Israel. The report details a corporate action regarding the company's capital structure following shareholder approval received on May 5, 2026.
Key Financial Metrics
This filing is a Current Report (Item 8.01) and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The only financial data point disclosed relates to the capital structure adjustment:
- Par Value Adjustment: The par value of ordinary shares will increase from $0.0135 per share to $0.135 per share.
- Warrant Exercise Price: Existing warrants (SLXNW) have an exercise price of $1,552.50 per share.
Material Changes
The primary material change announced is a 1-for-10 reverse share split of all issued and outstanding, and authorized but unissued, ordinary shares. Key details include:
- Effective Date: After the close of the market on May 28, 2026.
- Trading Resumption: Shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at the open on May 29, 2026.
- Ticker Symbol: The symbol "SLXN" will remain unchanged.
- Fractional Shares: No fractional shares will be issued; fractional entitlements for DTC participants will be rounded up to the nearest whole number.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the standard implications of a reverse split. The action is described as automatic, requiring no action from shareholders. The filing references a press release (Exhibit 99.1) for further details but does not include unusual items or contingencies in the text provided.
Investor Verification Checklist
- Verify the exact number of shares held prior to the May 28, 2026, close to calculate post-split holdings.
- Confirm the rounding methodology for fractional shares if holding a number of shares not divisible by 10.
- Review the attached press release (Exhibit 99.1) for any additional context on the rationale for the reverse split.
- Monitor the Nasdaq Capital Market listing status on May 29, 2026, to ensure trading resumes as scheduled.